Current evidence on mesenchymal stem cells for hip osteoarthritis: a narrative review.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2023-09-01 DOI:10.2217/rme-2023-0071

Mina Entessari, Leonardo P Oliveira

引用次数: 0

Abstract

There are limited data on the use of mesenchymal stem cell injections for hip osteoarthritis. The goal of this study was to evaluate the literature by analyzing outcomes and comparing methodologies. Online search of PubMed, SportsDiscus and Case Reports Keywords was completed using the keywords 'stem cells' and 'hip' and 'osteoarthritis'. Six studies met the inclusion and exclusion criteria. Five out the six studies had statistically significant improvement in patient reported outcomes after mesenchymal stem cell injections. Only two studies provided information on radiological changes and findings were positive. None of the studies reported major complications. Small series of non-randomized controlled trials completed to date in the use of mesenchymal stem cells for the treatment of hip osteoarthritis reported the procedures to be safe and provide a positive clinical response. Randomized controlled trials must be performed to further confirm mesenchymal stem cells as a treatment option for hip osteoarthritis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间充质干细胞治疗髋关节骨关节炎的最新证据:叙述性回顾。

关于使用间充质干细胞注射治疗髋关节骨关节炎的数据有限。本研究的目的是通过分析结果和比较方法来评价文献。使用关键词“干细胞”、“髋关节”和“骨关节炎”完成PubMed、SportsDiscus和病例报告关键词的在线搜索。6项研究符合纳入和排除标准。六项研究中有五项在注射间充质干细胞后患者报告的结果有统计学显著改善。只有两项研究提供了有关放射学变化的信息，结果是阳性的。没有一项研究报告有重大并发症。迄今为止完成的使用间充质干细胞治疗髋关节骨关节炎的小系列非随机对照试验报告该程序是安全的，并提供了积极的临床反应。必须进行随机对照试验以进一步证实间充质干细胞作为髋关节骨关节炎的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.